Clinical Trial Update: SNIFF - Combo INI+EMPA Trial [Phase 2]

View source ↗

Summary

Phase 2 clinical trial SNIFF combining INI and empagliflozin has completed with results posted for cognitive impairment-related indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Empagliflozin (empagliflozin)
• INI

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Mild Cognitive Impairment, Cognitive Impairment | Phase 2 | Status: COMPLETED | Results posted: 2025-10-21